Novel anti-pd-1 antibodies

Abstract

The present disclosure provides monoclonal antibodies against protein programmed cell death 1 (PD-1), which can block the binding of PD-1 ligands to PD-1, and therefore block the inhibitory function of PD-1 ligands on PD-1 expressing T cells. The antibodies of disclosure provide very potent agents for the treatment of multiple cancers via modulating human immune function.

1 - 34 . (canceled) 
     
     
         35 . A monoclonal anti-programmed cell death 1 (PD-1) antibody comprising a heavy chain variable region comprising SEQ ID NO: 53; a light chain variable region comprising SEQ ID NO: 67; and a human constant region of IgG4 isotype. 
     
     
         36 . The antibody of  claim 35 , wherein the antibody is a fully human monoclonal antibody. 
     
     
         37 . A pharmaceutical composition comprising the antibody of  claim 35 . 
     
     
         38 . An isolated polynucleotide encoding the antibody of  claim 35 . 
     
     
         39 . A vector comprising the isolated polynucleotide of  claim 38 . 
     
     
         40 . A host cell comprising the vector of  claim 39 . 
     
     
         41 . A method of treating a condition associated with PD-1 in an individual, comprising: administering a therapeutically effective amount of the antibody of  claim 35 . 
     
     
         42 . The method of  claim 41 , wherein the condition is cancer or chronic viral infection.